Delivery Order SPE2DB24D9223-SPE2DB25FKELF

The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, valued at $16,249.95, was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. The contract does not utilize a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion comprehensive pharmaceutical supply agreement valid through November 2026 that enables the agency to procure a broad range of medications and medical supplies for Department of Defense healthcare facilities worldwide.

DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its status as a woman-owned small business to secure consistent contract awards from the DLA. The company's extensive portfolio includes branded and generic prescription drugs, biologics, vaccines, and specialty medications supporting military health systems globally. Stelara, a biologic immunosuppressant medication used in the treatment of various autoimmune conditions, represents one of many specialty pharmaceutical products the vendor delivers through its DLA partnership, demonstrating the company's capability to supply both high-cost specialty treatments and routine medications to government healthcare operations.